BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7987979)

  • 1. Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil.
    Thiberville L; Compagnon P; Moore N; Bastian G; Richard MO; Hellot MF; Vincent C; Kannass MM; Dominique S; Thuillez C
    Cancer Chemother Pharmacol; 1994; 35(1):64-70. PubMed ID: 7987979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Puzzles in the clinical pharmacokinetics of fluorouracil.
    Desoize B; Bouche O; Berthiot G; Coninx P
    Anticancer Res; 1998; 18(6B):4607-10. PubMed ID: 9891526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses.
    Ozaki Y; Imamaki H; Ikeda A; Oura M; Nakagawa S; Funakoshi T; Kataoka S; Nishikawa Y; Horimatsu T; Yonezawa A; Matsubara T; Yanagita M; Muto M; Watanabe N
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):693-699. PubMed ID: 33011861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion].
    Czejka M; Schüller J; Schernhammer E; Bandak S
    Pharmazie; 1995 Jun; 50(6):416-9. PubMed ID: 7651979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
    Lynch TJ; Kalish LA; Kass F; Strauss G; Elias A; Skarin A; Shulman L; Sugarbaker D; Frei E
    Cancer; 1994 Feb; 73(4):1171-6. PubMed ID: 8313319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous-infusion cisplatin, 5-fluorouracil, and bolus methotrexate in the treatment of advanced non-small cell lung cancer.
    Lynch TJ; Clark JR; Kalish LA; Fallon BG; Elias AD; Skarin A; Frei E
    Cancer; 1992 Oct; 70(7):1880-5. PubMed ID: 1326396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer.
    Ellis PA; Talbot DC; Nicolson MC; Priest K; Ashley S; Smith IE
    Br J Cancer; 1995 Jun; 71(6):1315-8. PubMed ID: 7779730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
    Nakano T; Ikegami H; Nakamura S; Kawase T; Nishikawa H; Yokota S; Yoshida M; Tachibana T; Igarashi T; Komuta K; Higashino K
    Br J Cancer; 1996 May; 73(9):1096-100. PubMed ID: 8624270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.
    Nishikawa Y; Funakoshi T; Horimatsu T; Miyamoto S; Matsubara T; Yanagita M; Nakagawa S; Yonezawa A; Matsubara K; Muto M
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):629-633. PubMed ID: 28204913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.
    Joel SP; Papamichael D; Richards F; Davis T; Aslanis V; Chatelut E; Locke K; Slevin ML; Seymour MT
    Clin Pharmacol Ther; 2004 Jul; 76(1):45-54. PubMed ID: 15229463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
    Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
    Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.
    Fety R; Rolland F; Barberi-Heyob M; Hardouin A; Campion L; Conroy T; Merlin JL; Rivière A; Perrocheau G; Etienne MC; Milano G
    Clin Cancer Res; 1998 Sep; 4(9):2039-45. PubMed ID: 9748117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer.
    Kunitoh H; Watanabe K
    J Clin Oncol; 1994 Jan; 12(1):83-9. PubMed ID: 8270989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
    Vokes EE; Moormeier JA; Ratain MJ; Egorin MJ; Haraf DJ; Mick R; Weichselbaum RR
    Cancer Chemother Pharmacol; 1992; 29(3):178-84. PubMed ID: 1733549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
    Yamada Y
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of 5-day continuous infusion of cis-diamminedichloroplatinum(II) in the treatment of non-small-cell lung cancer.
    Saito Y; Mori K; Tominaga K; Yokoi K; Miyazawa N
    Cancer Chemother Pharmacol; 1990; 26(6):389-92. PubMed ID: 2171793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients.
    Arshad U; Ploylearmsaeng SA; Karlsson MO; Doroshyenko O; Langer D; Schömig E; Kunze S; Güner SA; Skripnichenko R; Ullah S; Jaehde U; Fuhr U; Jetter A; Taubert M
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):711-722. PubMed ID: 32152679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic absorption of 5-fluorouracil during vitrectomy.
    Creten O; Spileers W; Stalmans P
    Am J Ophthalmol; 2006 Jul; 142(1):194-6. PubMed ID: 16815286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck.
    Dasmahapatra KS; Citrin P; Hill GJ; Yee R; Mohit-Tabatabai MA; Rush BF
    J Clin Oncol; 1985 Nov; 3(11):1486-9. PubMed ID: 4056841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.